published meta-analysis   sensitivity analysis   studies

sarilumab in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsREMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07] 0.51[0.25; 1.07]REMAP-CAP sarilumab, 202110%442moderatenot evaluable clinical improvementdetailed resultsREMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78] 1.76[1.12; 2.78]REMAP-CAP sarilumab, 202110%450moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-16 00:11 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 553,628,646,645 - roots T: 290